The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.

Company profile
Ticker
LMNX
Exchange
Website
CEO
Nachum Shamir
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
3M • Boston Scientific • Baxter International • Stryker • Becton, Dickinson And • Teleflex • Resmed • Hill-Rom • Nuvasive • Integra Lifesciences ...
SEC CIK
Corporate docs
Subsidiaries
Luminex International, Inc. • Luminex B.V. • Luminex 2 B.V. • Luminex 3 B.V. • Luminex Debt Holding, LLC • Nanosphere, LLC • Luminex Molecular Diagnostics, Inc. • Luminex Trading (Shanghai) Company Limited, a limited liability company • Luminex Japan Corporation Ltd. • Labpac Pty Ltd ...
IRS number
742747608
LMNX stock data
Calendar
5 May 21
26 Jun 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 271.56M | 271.56M | 271.56M | 271.56M | 271.56M | 271.56M |
Cash burn (monthly) | 12.62M | (no burn) | (no burn) | (no burn) | 7.19M | (no burn) |
Cash used (since last report) | 187.63M | n/a | n/a | n/a | 106.9M | n/a |
Cash remaining | 83.93M | n/a | n/a | n/a | 164.66M | n/a |
Runway (months of cash) | 6.7 | n/a | n/a | n/a | 22.9 | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Jul 21 | Todd C. Bennett | Common Stock | Sale back to company | Dispose D | No | No | 37 | 30,266 | 1.12M | 0 |
14 Jul 21 | Todd C. Bennett | Common Stock | Sale back to company | Dispose D | No | No | 37 | 17,342 | 641.65K | 30,266 |
14 Jul 21 | Todd C. Bennett | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 23.09 | 72,976 | 1.69M | 0 |
14 Jul 21 | Todd C. Bennett | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 24.43 | 16,191 | 395.55K | 0 |
14 Jul 21 | Todd C. Bennett | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 21.98 | 12,849 | 282.42K | 0 |
14 Jul 21 | Todd C. Bennett | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 18.04 | 14,652 | 264.32K | 0 |
14 Jul 21 | Collins Charles J. | Common Stock | Sale back to company | Dispose D | No | No | 37 | 26,550 | 982.35K | 0 |
14 Jul 21 | Collins Charles J. | Common Stock | Sale back to company | Dispose D | No | No | 37 | 23,244 | 860.03K | 26,550 |
14 Jul 21 | Collins Charles J. | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 23.09 | 64,868 | 1.5M | 0 |
14 Jul 21 | Collins Charles J. | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 24.43 | 18,888 | 461.43K | 0 |
Institutional ownership, Q4 2021
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 4 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 1 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Huntington National Bank | 1 | $0 |
Financial report summary
?Competition
Abbott Laboratories • Bio-Rad Laboratories • Perkinelmer • Thermo Fisher Scientific • Danaher • QuidelOrtho • Accelerate Diagnostics • Meridian Bioscience • Hologic • QiagenManagement Discussion
- ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
- This Quarterly Report on Form 10-Q contains statements that are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide our current expectations of forecasts of future events. All statements other than statements of current or historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding our future financial position, business strategy, impact of the reimbursement landscape, products including ARIES, VERIGENE, NxTAG, Muse, Guava, easyCyte, InCyte, Amnis, ImageStream, FlowSight and CellStream, assay sales, consumable sales patterns and bulk purchases, budgets, system sales, anticipated gross margins, liquidity, cash flows, projected costs and expenses, taxes, deferred tax assets, regulatory approvals or the impact of laws or regulations applicable to us, plans and objectives of management for future operations, and impact of prior acquisitions or future acquisitions, integration and the expected benefit of our acquisitions are all forward-looking statements. The words “anticipate,” “believe,” “continue,” “should,” “estimate,” “expect,” “intend,” “may,” “plan,” “projects,” “will” and similar expressions as they relate to us, are intended to identify forward-looking statements. These statements are based on our current plans and actual future activities, and our financial condition and results of operations may be materially different from those set forth in the forward-looking statements as a result of known or unknown risks and uncertainties, including, among other things:
- •risks and uncertainties related to our proposed acquisition by DiaSorin S.p.A;
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
absence, agree, agreed, analyst, antitrust, asserting, attract, audit, azioni, bifurcated, billion, BNP, breach, bridge, building, cancelled, categorical, CE, certificate, Chancery, choice, Committee, confidence, constant, consummated, consummation, coupled, court, cumulative, customary, Delaware, deny, description, DGCL, Diagonal, DiaSorin, director, discourage, dissenting, district, diversion, doctrine, duty, easyCheck, Economy, endorsement, exclusive, exhibit, expiration, expired, fee, fiduciary, firm, FlowCellect, flu, forum, French, fullest, GuavaSoft, hand, home, inapplicable, INSPIRE, investor, Italy, judicial, loan, located, LumAvidin, LX, MagPlex, Mark, matter, Mediobanca, MicroPlex, Ministry, mortgage, mutually, Nexin, organized, outlook, owed, owner, Parent, proceeding, prove, purport, raw, receipt, recovery, relationship, Republic, resolution, retain, retrospective, RSV, SD, SeroMAP, Simplifying, slightly, societ, solicit, SpeedBead, sponsorship, superior, surviving, SYNCT, syncytial, syndicate, text, thereunder, timeframe, Topic, trademark, unclear, unenforceable, UniCredit, ViaCount, waiting, wholly, writing, wrote, xPONENT, XYP
Removed:
absolute, accurate, accurately, achieve, acid, added, adding, addressed, adhere, advantage, affordable, aid, Alex, amplification, analyte, analyze, analyzed, animal, antibiotic, applied, approved, architecture, area, assure, attaching, automate, automation, Azar, back, bacteria, barcode, batch, began, begin, benchtop, bind, biochemical, biomarker, blood, bonding, bringing, capture, captured, care, cartridge, CDF, ceasing, cell, centered, certified, CFR, chemistry, claimed, cleared, CLIA, clinically, Clostridium, coated, collectability, collected, collecting, color, colored, combine, Commissioner, commitment, compare, competing, complex, complexity, computer, conclusion, conclusive, conducted, congregation, continuance, contrast, correcting, Cosmetic, counterparty, counting, create, credit, culture, customizable, customizing, cytometer, database, dating, declaration, deducted, delaying, demonstrate, detail, detect, detected, detection, diagnosing, difficile, digital, discovery, discretion, displayed, dissolving, distinctive, distinctly, distinguish, distraction, distribute, DNA, doubtful, dye, efficient, efficiently, effort, EMD, emitting, ensuring, enteric, enzymatic, Epidemic, established, evidence, exercise, expensed, extraction, false, family, FDCA, flexibility, flexible, fluorescence, fluorescent, footprint, foundation, functional, gain, Gen, generate, genetic, geographic, gold, GPP, halt, healthcare, highly, history, hospital, hour, hydrogen, identity, illumination, imaging, immunologic, important, independent, individual, inexpensive, infection, informed, injected, innovative, inspection, instrumentation, interested, interface, involved, IRS, isoC, isoG, issue, IVD, labeling, labor, laser, leading, Likewise, magnetic, mandatory, maximum, MDx, meaningful, medicine, menu, met, microarray, microcapillary, microscopy, microsphere, microtiter, Millipore, mixed, mixture, moderate, modular, module, multiplex, NanoGrid, nanoparticle, nasopharyngeal, natural, naturally, newly, noted, nucleic, nucleotide, occurring, operator, optimized, ordered, outbreak, outweigh, pair, particle, patient, pattern, paying, performed, performing, permit, permitting, personalized, pharmacogenetic, plate, pooled, population, posed, positive, precision, prescribe, previously, pricing, probe, processing, produce, professional, proper, prospective, protein, Protocol, purification, purpose, qualitative, reclassified, recording, regimen, relief, remeasured, remotely, reporter, represent, reputation, researcher, resistance, restatement, restating, revised, revocation, revoke, revoked, room, RP, ruling, save, scalable, scanning, scientific, Secretary, section, seek, segment, select, sensitivity, sequential, signal, signature, simple, simultaneously, single, software, solution, spatial, specificity, spectrum, speed, STAT, stored, stream, supplier, supportable, surface, suspected, suspending, swab, syndromic, synthetic, targeted, technical, temporary, terminated, tested, therapeutic, threat, today, tracking, traditional, transition, tube, type, typically, ultimate, unapproved, unavailable, Universal, utilize, versatile, viability, viewed, vitro, waived, wide, widespread, yeast
Financial reports
Current reports
8-K
Termination of a Material Definitive Agreement
14 Jul 21
8-K
Other Events
9 Jul 21
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 21
8-K
Other Events
11 Jun 21
8-K
Other Events
26 May 21
8-K
Submission of Matters to a Vote of Security Holders
20 May 21
8-K
Entry into a Material Definitive Agreement
12 Apr 21
8-K
Departure of Directors or Certain Officers
24 Feb 21
8-K
Luminex Corporation Reports Fourth Quarter and Full-Year 2020 Results
8 Feb 21
8-K
Luminex Corporation Pre-Release of 4th Quarter 2020 Revenue
11 Jan 21
Registration and prospectus
15-12G
Securities registration termination
26 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 21
Proxies
DEFA14A
Additional proxy soliciting materials
11 Jun 21
DEFA14A
Additional proxy soliciting materials
26 May 21
DEFM14A
Proxy related to merger
20 May 21
PREM14A
Preliminary proxy related to merger
7 May 21
DEFA14A
Additional proxy soliciting materials
19 Apr 21
DEFA14A
Additional proxy soliciting materials
16 Apr 21
DFAN14A
Additional proxy materials by non-management
12 Apr 21
DEFA14A
Additional proxy soliciting materials
12 Apr 21
DEF 14A
Definitive proxy
31 Mar 21
DEFA14A
Additional proxy soliciting materials
31 Mar 21
Other
SD
Conflict minerals disclosure
28 May 20
SD
Conflict minerals disclosure
30 May 19
SD
Conflict minerals disclosure
30 May 18
SD
Conflict minerals disclosure
29 May 17
SD
Conflict minerals disclosure
26 May 16
SD
Conflict minerals disclosure
28 May 15
UPLOAD
Letter from SEC
12 Jun 14
CORRESP
Correspondence with SEC
10 Jun 14
UPLOAD
Letter from SEC
5 Jun 14
CORRESP
Correspondence with SEC
4 Jun 14
Ownership
4
LUMINEX / KENNETH A SAMET ownership change
15 Jul 21
4
LUMINEX / EDWARD A OGUNRO ownership change
15 Jul 21
4
LUMINEX / KEVIN M MCNAMARA ownership change
15 Jul 21
4
LUMINEX / Dijuana K Lewis ownership change
15 Jul 21
4
LUMINEX / JIM D KEVER ownership change
15 Jul 21
4
LUMINEX / THOMAS W ERICKSON ownership change
15 Jul 21
4
LUMINEX / Stephen L. Eck ownership change
15 Jul 21
4
LUMINEX / Eric Shapiro ownership change
15 Jul 21
4
LUMINEX / NACHUM SHAMIR ownership change
15 Jul 21
4
LUMINEX / Richard W. Rew II ownership change
15 Jul 21
Patents
Design
Sample processing instrument
7 Jun 22
Inventors: Lucas Wade
Utility
Chimeric primers with hairpin conformations and methods of using same
3 May 22
Methods and compositions for nucleic acid amplification, detection, and genotyping techniques are disclosed.
Utility
Probes for improved melt discrimination and multiplexing in nucleic acid assays
1 Mar 22
Methods and compositions for the detection and quantification of nucleic acids are provided.
Utility
User Interface for a Fluorescence Assay
13 Jan 22
A fluorescence assay device performs a fluorescence assay of one or more samples including fluorescent materials, causing a plurality of sets of datapoint to be stored relating to received fluorescence emitted by the fluorescent materials.
Utility
Real-time Multiplexed Hydrolysis Probe Assay Using Spectrally Identifiable Microspheres
7 Oct 21
Methods and compositions for the detection and quantification of nucleic acids are provided.
Transcripts
2020 Q4
Earnings call transcript
9 Feb 21
2020 Q3
Earnings call transcript
8 Nov 20
2020 Q2
Earnings call transcript
4 Aug 20
2020 Q1
Earnings call transcript
4 May 20
2019 Q4
Earnings call transcript
10 Feb 20
2019 Q3
Earnings call transcript
4 Nov 19
2019 Q2
Earnings call transcript
31 Jul 19
2019 Q1
Earnings call transcript
6 May 19
2018 Q4
Earnings call transcript
4 Feb 19
2018 Q3
Earnings call transcript
5 Nov 18